Friday, May 1, 2026
← Back to archivePolicy
Policy•Fierce Pharma•May 1, 2026
Amarox recalls batch of antidepressants in UK over packaging mix-up
background ▾
- •Voluntary recall of sertraline batch due to packaging mix-up involving two different antidepressants in a single package
AmaroxHetero Groupsertraline
→ Read original articlePolicy•Fierce Biotech•Apr 30, 2026
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
background ▾
- •ODAC voted against camizestrant approval, with the FDA determining the early-switch treatment paradigm lacks established clinical benefit despite a 56% PFS improvement in Serena-6
- •FDA's core objection centers on trial design flaws: no crossover permitted, PFS not measured from standard time point, and failure to demonstrate long-term benefit versus standard of care (waiting until progression)
- •The decision carries broader regulatory implications—FDA explicitly flagged concern that approving camizestrant would set a problematic precedent for early intervention strategies in future oncology trials across multiple tumor types without long-term efficacy evidence
AstraZenecacamizestrant
→ Read original articlePolicy•Fierce Pharma•May 1, 2026
Europe’s drug regulator sets up new group to counter vaccine hesitancy
background ▾
- •EMA is formalizing institutional response to vaccine hesitancy through dedicated advisory infrastructure, indicating the regulator views confidence-building as within its strategic remit
- •The initiative addresses a material public health threat in Europe but relies on advisory mechanisms rather than regulatory or legislative tools, limiting immediate impact potential
European Medicines Agency
→ Read original articlePolicy•Fierce Pharma•May 1, 2026
Novartis rounds out $23B US investment push with plans for North Carolina API plant
background ▾
- •Novartis is expanding US-based API manufacturing capacity with a specialized facility designed for solid-dose formulations and RNA therapeutics, supporting nearshoring and supply chain diversification goals
- •This North Carolina facility is part of a $23 billion US investment initiative, indicating substantial pharma industry commitment to domestic manufacturing infrastructure post-pandemic
- •Watch for facility operational timelines, capacity ramp-up rates, and potential impacts on Novartis's cost structure and supply chain flexibility for RNA and traditional small-molecule programs
Novartis
→ Read original articlePolicy•STAT News•May 1, 2026
Opinion: The psychedelic revolution is leaving behind people of color
background ▾
- •Trump's executive order directing federal agencies to streamline regulatory pathways and expand psychedelic clinical trials represents significant policy acceleration for a drug class transitioning from fringe to mainstream pharmaceutical investment.
- •Racial disparities in psychedelic access and research are substantial: white Americans use psychedelics at 3.5× the rate of racial/ethnic minorities, despite minorities experiencing higher rates of trauma and conditions psychedelics may treat.
- •Watch for: equity metrics in upcoming psychedelic clinical trials; FDA guidance on expedited pathways; whether Big Pharma investments in psychedelics will fund research specifically in underrepresented populations.
AbbViePerception Neuroscience (implied as bretisilocin developer)bretisilocinibogainepsilocybin
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 30, 2026
Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy
background ▾
- •Leo Pharma acquired Replay's preclinical HSV gene therapy platform targeting dystrophic epidermolysis bullosa and other rare genetic skin diseases for $50M upfront plus milestone payments
- •The deal underscores Leo's strategic commitment to rare dermatology and next-generation gene therapy following its prior $105M Boehringer Ingelheim transaction for Spevigo (generalized pustular psoriasis)
- •Key development milestone: advancement of the dystrophic epidermolysis bullosa topical gel candidate through IND-enabling studies and clinical development timelines
Leo PharmaReplay TherapeuticsSpevigodystrophic epidermolysis bullosa gene therapy (Replay HSV platform)
→ Read original articleMarket Access•Fierce Biotech•Apr 30, 2026
BeOne signs $2B deal for option on preclinical trispecific antibody from China’s Huahui
background ▾
- •BeOne has optioned a preclinical trispecific targeting three immune/angiogenic pathways (PD-1/CTLA-4/VEGF-A) with potential to address combination therapy resistance in cancer
- •The deal structure ($20M upfront, $100M option fee, up to $1.9B milestones) reflects commercial-stage valuation despite preclinical status, suggesting BeOne's confidence in the platform or strategic need to build multispecific depth
- •Watch for BeOne's exercise of the option and timeline to IND—early clinical data from BG-T187 will likely inform decisions on HH160 advancement and resource allocation
BeOne MedicinesHuahui HealthHH160BG-T187Brukinsa
→ Read original articleMarket Access•Fierce Pharma•May 1, 2026
Verastem launches ‘Reimagine’ campaign to move ovarian cancer drugs into earlier lines
background ▾
- •Verastem is pursuing market expansion strategy by repositioning its ovarian cancer combination therapy toward earlier lines of treatment rather than later-line use
Verastem Oncology
→ Read original articleMarket Access•Fierce Pharma•May 1, 2026
BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
background ▾
- •BMS's new product revenue now exceeds legacy portfolio revenue, validating the company's portfolio transition strategy
- •Camzyos faces emerging competition, but BMS stated it is 'well prepared,' indicating confidence in differentiation or market positioning
Bristol Myers SquibbCamzyosmavacamtene
→ Read original articleMarket Access•Fierce Pharma•May 1, 2026
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
background ▾
- •Foundayo's early commercial launch is underperforming Novo Nordisk's Wegovy in initial uptake despite Lilly's aggressive obesity market positioning
- •Lilly management and allied analysts express confidence in long-term prospects despite slower-than-expected early sales trajectory
Eli LillyNovo NordiskFoundayoWegovy
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 30, 2026
BMS calls time on Zymeworks collab, ending work on phase 1 cancer bispecific
background ▾
- •BMS has discontinued a CD40/FAP bispecific in phase 1, ending the legacy Celgene-Zymeworks collaboration and eliminating $313M in potential milestones for Zymeworks
- •The termination reflects BMS's ongoing portfolio prioritization efforts, signaling that even early-stage oncology programs must meet high thresholds for continued investment
- •Watch whether Zymeworks can independently advance the bispecific or pivot to other partnerships given its stated strategy to become a royalty-driven organization
Bristol Myers SquibbZymeworksCelgeneCD40/FAP bispecific (unnamed)Ziihera
→ Read original articleClinical Trials•Fierce Biotech•May 1, 2026
Amgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 data
background ▾
- •Amgen's Horizon acquisition yielded limited pipeline value; only one investigational candidate (AMG 732) remains in development from the $27.8B deal
- •Adezkibart failure in Sjögren's reflects challenges with FMS-like tyrosine kinase 3 ligand inhibition; dazodalibep's CD40 ligand mechanism represents Amgen's pivot to upstream T/B cell targeting
- •Watch dazodalibep phase 3 data readouts expected later in 2024 to assess viability of Amgen's remaining Sjögren's program and validate CD40 ligand as therapeutic target
AmgenHorizon TherapeuticsAstellasadezkibartAMG 329anvumetostat
→ Read original articleClinical Trials•Endpoints News•Apr 30, 2026
FDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
background ▾
- •The FDA oncology advisory committee rejected AstraZeneca's proposed trial design paradigm by a 6-3 vote, signaling skepticism among expert advisors about the novel approach
- •The committee's concerns about establishing new precedent in oncology trial design could impact how AstraZeneca structures its late-stage program going forward
- •Monitor AstraZeneca's response and whether the company seeks to modify the trial design, request a Type C meeting with FDA, or appeal the advisory committee's reasoning
AstraZeneca
→ Read original articleClinical Trials•Fierce Biotech•Apr 30, 2026
Indivior warns of ‘significant impact’ on R&D team after opioid use disorder drug fails phase 2
background ▾
- •INDV-2000 phase 2 missed primary endpoint but showed exploratory signals at 200-mg dose for cocaine/polysubstance abstinence, positioning it as a potential business development asset rather than an internally-developed program
- •Dual program termination (INDV-2000 and INDV-6001) indicates significant R&D restructuring with expected cost savings, though specific headcount impact and timeline remain undisclosed
- •Watch for: partner interest in acquiring INDV-2000; scope and timing of Indivior R&D restructuring; potential pivots in the company's OUD portfolio strategy given buprenorphine asset return
Indivior PharmaceuticalsAlar PharmaceuticalsINDV-2000INDV-6001buprenorphine
→ Read original articleClinical Trials•Endpoints News•Apr 30, 2026
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk
background ▾
- •Krazati failed its confirmatory trial in second-line colorectal cancer, putting FDA approval at imminent risk for this indication
- •This represents a major setback for BMS's oncology portfolio and suggests potential limitations in the drug's mechanism of action or patient selection strategy
- •Watch for BMS's regulatory filing decisions in the coming weeks—the company may withdraw its application, seek alternative indications, or attempt to reposition the drug based on post-hoc subgroup analyses
Bristol Myers SquibbKrazatiseribantumab
→ Read original article